ArticleFertility Preservation in Patients With Gynecologic Cancer—Part II Current Options and the Ethics of OncofertilityLange, Sara MD; Hurst, Bradley S. MD; Matthews, Michelle L. MD; Tait, David L. MDAuthor Information Dr. Lange is Resident Physician, Dr. Hurst is Director of Assisted Reproduction, Dr. Matthews is Associate Director, Reproductive Endocrinology, and Dr. Tait is Associate Director of Gynecologic Oncology, Levine Cancer Institute, Carolinas Medical Center, PO Box 32861, Charlotte, NC 29232; E-mail: [email protected]. All faculty and staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations pertaining to this educational activity. The authors have disclosed that the U.S. Food and Drug Administration has not approved the use of gonadotropin-releasing hormone agonists for ovarian suppression. Lippincott Continuing Medical Education Institute, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Lippincott Continuing Medical Education Institute, Inc., designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. To earn CME credit, you must read the CME article and complete the quiz and evaluation on the enclosed answer form, answering at least seven of the 10 quiz questions correctly. This activity expires on July 30, 2014. Postgraduate Obstetrics & Gynecology: July 31, 2013 - Volume 33 - Issue 14 - p 1-5 doi: 10.1097/01.PGO.0000434086.10618.cf Buy CME Test Metrics © 2013 by Lippincott Williams & Wilkins, Inc.